Table 1.
Baseline characteristics
| Characteristica | Decitabine x 5 days (N=28) |
Decitabine x 10 days (N=43) |
|---|---|---|
| Age (years) | 77 [70–80] | 78 [69–82] |
| WBC (109/L) | 2.0 [1.5–3.9] | 3.2 [1.9–10.6] |
| Hemoglobin (g/dL) | 9.4 [8.7–9.8] | 9.2 [9.0–9.7] |
| Platelets (109/L) | 25 [14–60] | 37 [24–83] |
| BM blasts (%) | 40 [29–68] | 46 [25–64] |
| ECOG performance status | ||
| 0–1 | 18 (64) | 30 (70) |
| 2–3 | 10 (36) | 13 (30) |
| s-AML/t-AML | 13 (46) | 18 (42) |
| Cytogenetics | ||
| Diploid | 8 (29) | 10 (23) |
| −5, −7 and/or complex | 13 (46) | 24 (56) |
| Others | 5 (18) | 6 (14) |
| IM/ND | 2 (7) | 3 (7) |
| Mutations | ||
| ASXL1 | 3/19 (16) | 2/34 (6) |
| DNMT3A | 3/24 (13) | 6/42 (14) |
| EZH2 | 1/22 (5) | 1/39 (3) |
| FLT3-ITD | 2/25 (8) | 2/42 (5) |
| NPM1 | 1/24 (4) | 8/42 (19) |
| IDH1/2 | 6/25 (24) | 14/42 (33) |
| JAK2 | 3/24 (13) | 1/42 (2) |
| KRAS/NRAS | 2/24 (8) | 4/42 (10) |
| PTPN11 | 0/21 (0) | 4/38 (6) |
| RUNX1 | 5/19 (26) | 2/35 (6) |
| TET2 | 1/19 (5) | 8/36 (22) |
| TP53 | 7/24 (29) | 17/41 (41) |
a
Continuous variables are listed as median [interquartile range] and categorical variables as n (%)
WBC, white blood cell; BM, bone marrow; ECOG, Eastern Cooperative Oncology Group; s-AML/t-AML, secondary- or therapy-related AML; IM/ND, insufficient metaphases/not done